Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tPA versus therapeutic UFH versus usual care in severe COVID-19
IRCT20200515047456N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tissue-plasminogen activator and heparin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Improvement in oxygenation, SOFA score improvement and 1 more. Started Jun 2020; status: completed.
02
Drugs
tissue-plasminogen activatorheparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200515047456N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200515047456N1.